Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. The company holds an agreement with National Research Council of Canada Industrial Research Assistance Program to support research and development of liquid biopsy assay for the early detection and screening of lung cancer. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
Stock data | 2024 | Change |
---|---|---|
Price | $0.18362774982555363 | N/A |
Market Cap | $16.69M | N/A |
Shares Outstanding | 90.89M | N/A |
Employees | 0 | N/A |